ADVANCED SOLID CANCER
Clinical trials for ADVANCED SOLID CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID CANCER trials appear
Sign up with your email to follow new studies for ADVANCED SOLID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called APX-343A, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shows any si…
Matched conditions: ADVANCED SOLID CANCER
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 07:34 UTC
-
New hope for advanced cancer: experimental drug MHB046C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB046C in 200 adults with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug by IV and are closely monitored for side effects…
Matched conditions: ADVANCED SOLID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for advanced cancer? first human trial of SIM0609 begins
Disease control Recruiting nowThis early-stage study tests a new drug, SIM0609, in 232 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose, while also watching for any signs that it might shrink tumors. This is…
Matched conditions: ADVANCED SOLID CANCER
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug targets Hard-to-Treat cancers by breaking down mutant protein
Disease control Recruiting nowThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose, then testing how well it works in …
Matched conditions: ADVANCED SOLID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC